The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Options for Treatment-Resistant RA

New Options for Treatment-Resistant RA

October 14, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New enthusiasm is emerging among rheumatologists based on trial results for filgotinib and U.S Food and Drug Administration (FDA) approval of upadacitinib—both Janus kinase (JAK) inhibitor drug therapies, creating new treatment options for patients with treatment-resistant rheumatoid arthritis (RA), according to Mark Genovese, MD, a rheumatologist and clinical chief in the Division of Immunology and Rheumatology at Stanford University, Calif.

You Might Also Like
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • FDA Approves Upadacitinib for RA
  • RA Treatment Options: Researchers Explore Groundwork for New Therapies
Also By This Author
  • The ACR Releases New Telemedicine Position Statement

Dr. Genovese works as a trialist and consultant with Gilead and AbbVie, the companies responsible for developing these emerging JAK-inhibitor treatments. He has served as lead investigator in multi-phase, randomized, controlled clinical trials for both drugs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Other JAK inhibitors currently on the market include tofacitinib and baricitinib.

Treatment Response
On Aug. 16, upadacitinib was approved by the FDA based on published clinical trial results that included findings from a phase 3 trial published in July 2019.1,2 In this clinical trial, 1,629 RA patients who had an inadequate response to methotrexate were randomized to receive 15 mg of upadacitinib once daily, placebo or 40 mg of adalimumab every other week while continuing a stable background dose of methotrexate. The results: Upadacitinib was superior to placebo and adalimumab for improving physical function and symptoms in RA patients who were receiving background methotrexate. Specifically, as measured by ACR20, 71% of upadacitinib-treated patients showed improvement compared with 36% of placebo-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It is impressive to see a new therapy demonstrate superiority vs. a TNF inhibitor plus methotrexate,” Dr. Genovese says.

Up to Week 26, adverse events, including serious infections, were comparable between the upadacitinib and adalimumab groups. The proportion of serious adverse events and events leading to treatment discontinuation was highest in the adalimumab group. Meanwhile, the upadacitinib group showed the highest proportion of patients with herpes zoster and creatine phosphokinase elevations.

In a randomized, controlled phase 3 clinical trial of filgotinib, 448 patients with active RA who had an inadequate response or intolerance to one or more biologic disease-modifying antirheumatic drugs (DMARDS) were assessed. An ACR20 clinical response was achieved at Week 12 in 66% of patients treated with 200 mg of filgotinib and 57.5% of patients treated with 100 mg of filgotinib, compared with 31.1% of placebo-treated patients. The most common adverse events were nasopharyngitis at 10.2% for 200 mg of filgotinib; headache, nasopharyngitis and upper respiratory infection (5.9% each) for 100 mg filgotinib; and RA (6.1%) for placebo.3

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“One of the more impressive aspects in this trial was the level response in taking a fairly refractory group of active RA patients and achieving strong, low disease activity and remission outcomes,” Dr. Genovese says.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: drug treatment, filgotinib, Rheumatoid Arthritis (RA), upadacitinib

You Might Also Like:
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • FDA Approves Upadacitinib for RA
  • RA Treatment Options: Researchers Explore Groundwork for New Therapies
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.